Cover Image
市場調查報告書

MediPoint:人工心臟瓣膜 - 全球市場的分析與預測

MediPoint: Prosthetic Heart Valves - Global Analysis and Market Forecasts

出版商 GlobalData 商品編碼 329821
出版日期 內容資訊 英文 254 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:人工心臟瓣膜 - 全球市場的分析與預測 MediPoint: Prosthetic Heart Valves - Global Analysis and Market Forecasts
出版日期: 2015年02月06日 內容資訊: 英文 254 Pages
簡介

全球人工心臟瓣膜市場,預期到2020年是規模成長至10億美元的動態市場。根據介入心臟病學領域的最近進步,患者的臨床結果大幅度改善。

本報告提供全球人工心臟瓣膜市場相關調查分析、競爭情形、上市、開發中產品、現在、新興企業、各市場區隔的市場分析等系統性資訊。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 概要
  • 適應
  • 臨床表現
  • 臨床結果
  • 技術的應用
  • 市場進入
  • 臨床試驗的影響
  • 崇尚名牌
  • 採用
  • 法規
  • 償付
  • 治療趨勢
  • 法規問題/回收
  • M&A/主要的聯盟
  • 經濟影響

第4章 未滿足需求

  • 提供和嵌入
  • 性能
  • Crimping
  • 支架置入
  • 可替換小葉
  • 栓塞預防
  • 心律調節器的安裝

第5章 市場機會分析

  • 概要
  • TAVR的新興市場
  • 延長生物心臟瓣膜的壽命
  • valve-in-valve術(重新置換)
  • 經二尖瓣置換
  • 球囊瓣膜成形術

第6章 推動市場要素與阻礙

  • 推動因素
  • 障礙
  • 替代

第7章 競爭評估

  • 概要
  • 各功能的分類
  • 市場動態分析
  • 產品簡介

第8章 開發平台評估

  • 概要
  • 產品簡介

第9章 值得注意的臨床試驗

  • 概要
  • 產品簡介

第10章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • AorTech International
    • Boston Scientific
    • Braile Biomedica
    • CardiAQ Valve Technologies
    • Claret Medical
    • Colibri Heart Valve
    • Cytograft Tissue Engineering
    • Direct Flow Medical
    • Edwards Lifesciences
    • Heart Leaflet Technologies
    • JenaValve Technology
    • Leman Cardiovascular
    • Micro Interventional Devices
    • Neovasc
    • On-X Life Technologies, Inc.
    • Perouse Medical
    • Sorin Group
    • St. Jude Medical
    • Symetis
    • Transcatheter Technologies GmbH
    • TTK Healthcare
    • ValveXchange

第11章 策略性競爭評估

  • 企業的市場佔有率

第12章 市場預測:市場部門別

  • 市場區隔佔有率

第13章 市場預測:各地區

  • 全球概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度
  • 巴西

第14章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0210MAR

The global prosthetic heart valves (PHV) market is a dynamic, billion-dollar market that is expected to grow through 2020. Recent advancements in the field of interventional cardiology have greatly improved clinical outcomes for patients. Prosthetic heart valves, including mechanical valves, tissue valves, and transcatheter valves, can be used to treat patients with valvular heart disease affecting the aortic or mitral valves. They can be delivered either via open-heart surgery or transcatheter aortic valve implantation (TAVR).

The rising prevalence of disease and associated risk factors, an aging population, and improved clinical outcomes with minimally invasive techniques are expected to drive the growth of the global prosthetic heart valve market. Emerging technologies such as repositionable and retrievable transcatheter aortic valves will optimize clinical outcomes for patients. With improvements in the design of transcatheter valves, they have the potential to become the standard of treatment for valvular heart disease in the future.

This report focuses on the global prosthetic heart valves market in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, China, India, and Brazil) for treating valvular heart disease. This report provides insight into the competitive landscape, the marketed and pipeline products, the current and emerging players, and market analysis of each segment. The report identifies the unmet needs in the market while providing an understanding of physicians' perceptions and decision-making processes in using and evaluating the adoption of different types of prosthetic heart valves.

Highlights

Key Questions Answered

  • What is the current and future prosthetic heart valves market outlook in the developed and emerging markets? What trends are affecting the global market?
  • Which are the key, high growth markets that valve manufacturers should expand into? Which markets are growing the fastest, and what are the top-selling products in each segment?
  • What are the unmet needs with PHVs currently on the market? How will emerging technologies such as repositionable and retrievable valves fulfill these unmet needs?
  • What clinical factors and technical specifications influence a physician to use one type of valve over another? What is physician perception and market outlook of PHV?
  • What are the challenges and complications of TAVR that have hindered widespread adoption?
  • With developing the next-generation of heart valves, what aspects of the technology are device manufacturers focused on optimizing? How will new entrants impact the global PHV market?

Scope

  • Overview of valvular heart disease, including anatomy, epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
  • Annualized total PHV market revenue by type of valve, direct and indirect costs of disease, procedure trends, and market outlooks by country through 2020.
  • Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in each region covered in the report, and implications of the emerging technologies on the market.
  • Pipeline analysis: Comprehensive data split across different stages of development, emerging trends and valve designs in development, including investigation of delivery and deployment methods, materials and coatings used, and sizes available.
  • Analysis of the current and future market competition in the global prosthetic heart valve market. Insightful review of the key industry drivers, opportunities, barriers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • "What Physicians Think" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading Interventional Cardiologists and Cardiac Surgeons from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Anatomy
  • 2.2. Epidemiology
  • 2.3. Related Reports

3. Industry Overview

  • 3.1. Overview
    • 3.1.1. Mechanical Heart Valves
    • 3.1.2. Tissue Heart Valves
    • 3.1.3. Transcatheter Heart Valves
  • 3.2. Indications
    • 3.2.1. Valvular Stenosis
    • 3.2.2. Valvular Regurgitation
  • 3.3. Clinical Presentation
    • 3.3.1. Diagnosis
    • 3.3.2. Risk Assessment Tools
  • 3.4. Clinical Outcomes
    • 3.4.1. Treatment Options
    • 3.4.2. Life Style Changes
    • 3.4.3. Complications
  • 3.5. Applications of Technology
  • 3.6. Market Access
    • 3.6.1. Purchasing Decisions
  • 3.7. Influence of Clinical Trials
  • 3.8. Brand Loyalty
  • 3.9. Adoption
  • 3.10. Regulation
    • 3.10.1. US
    • 3.10.2. 5EU
    • 3.10.3. APAC
    • 3.10.4. South America
  • 3.11. Reimbursement
    • 3.11.1. US
    • 3.11.2. 5EU
    • 3.11.3. APAC
    • 3.11.4. South America
  • 3.12. Procedure Trends
    • 3.12.1. Global Overview
    • 3.12.2. By Country
  • 3.13. Regulatory Issues/Recalls
    • 3.13.1. Portico TAVR Implants Halted Due to Safety Concerns
  • 3.14. M&A, Key Partnerships
    • 3.14.1. Licensing Agreement Between Symetis and Endoluminal Sciences
    • 3.14.2. Manufacturing Agreement Between Sorin Group and Boston Scientific
  • 3.15. Economic Impact
    • 3.15.1. Indirect Costs
    • 3.15.2. Direct Costs

4. Unmet Needs

  • 4.1. Delivery & Implantation
    • 4.1.1. Mechanism of Deployment
    • 4.1.2. Anchoring
    • 4.1.3. Retrievability
    • 4.1.4. Repositionability
    • 4.1.5. Artery Accessibility
    • 4.1.6. Rapid Pacing
    • 4.1.7. Coronary Ostia Occlusion
    • 4.1.8. Motorized Delivery Systems
  • 4.2. Performance
    • 4.2.1. Durability
    • 4.2.2. Thrombogenicity
    • 4.2.3. Effective Orifice Area
    • 4.2.4. Coefficient of Friction
  • 4.3. Crimping
  • 4.4. Stenting
  • 4.5. Replaceable Leaflets
  • 4.6. Embolic Protection
  • 4.7. Pacemaker Placement

5. Market Opportunity Analysis

  • 5.1. Overview
  • 5.2. Emerging Markets for TAVR
  • 5.3. Increasing Tissue Valve Lifespan
  • 5.4. Valve-in-Valve Procedures (Re-replacement)
  • 5.5. Transcatheter Mitral Valve Replacement
  • 5.6. Balloon Valvuloplasty

6. Market Drivers and Barriers

  • 6.1. Driver: Rising Disease Prevalence
  • 6.2. Driver: Multimodality Imaging
  • 6.3. Driver: Alternative Access Routes
  • 6.4. Driver: Lower Risk Patient Access
  • 6.5. Driver: Patient Demand and Awareness
  • 6.6. Driver: Advanced Computational Tools
  • 6.7. Driver: Rising Competition and Innovation
  • 6.8. Barrier: High Device and Procedure Cost
  • 6.9. Barrier: Burden of Rising Regulation
  • 6.10. Barrier: Medical Device Excise Tax
  • 6.11. Barrier: Proving Long-Term Efficacy
  • 6.12. Substitute: Valve Repair
  • 6.13. Substitute: Balloon Valvuloplasty

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Classification Based on Features
    • 7.2.1. Mechanical Heart Valves
    • 7.2.2. Tissue Heart Valves
    • 7.2.3. Transcatheter Heart Valves
  • 7.3. Market Dynamics Analysis
  • 7.4. Product Profiles
    • 7.4.1. Mechanical Heart Valves
    • 7.4.2. Tissue Heart Valves
    • 7.4.3. Transcatheter Heart Valves

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Product Profiles
    • 8.2.1. Cytograft Tissue Valve (Cytograft Tissue Engineering)
    • 8.2.2. Centera Valve (Edwards Lifesciences)
    • 8.2.3. Colibri Heart Valve (Colibri Heart Valve)
    • 8.2.4. Cormove (Perouse Medical)
    • 8.2.5. Endovalve (Micro Interventional Devices)
    • 8.2.6. HLT Transcatheter Valve System (Heart Leaflet Technology)
    • 8.2.7. Kalangos Valve (Leman Cardiovascular)
    • 8.2.8. Tiara Valve (Neovasc)
    • 8.2.9. Trinity Valve (Transcatheter Technologies GmbH)
    • 8.2.10. Vanguard Exchangeable Heart Valve System (ValveXchange)

9. Clinical Trials to Watch

  • 9.1. Overview
  • 9.2. CoreValve Evolut R (Medtronic)
  • 9.3. TRANSFORM Trial - Intuity Valve System (Edwards Lifesciences)
  • 9.4. PROACT Trial - On-X Plus 1.5 Mechanical Heart Valve (On-X Life Technologies)
  • 9.5. PARTNER II Trial - Sapien XT (Edwards Lifesciences)
  • 9.6. PARTNER III Trial - Sapien 3 (Edwards Lifesciences)
  • 9.7. REPRISE III IDE/PMA Trial - Lotus Valve System (Boston Scientific)
  • 9.8. SENTINEL-H Trial - Sentinel Cerebral Protection System (Claret Medical)

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. AorTech International
    • 10.3.2. Boston Scientific
    • 10.3.3. Braile Biomedica
    • 10.3.4. CardiAQ Valve Technologies
    • 10.3.5. Claret Medical
    • 10.3.6. Colibri Heart Valve
    • 10.3.7. Cytograft Tissue Engineering
    • 10.3.8. Direct Flow Medical
    • 10.3.9. Edwards Lifesciences
    • 10.3.10. Heart Leaflet Technologies
    • 10.3.11. JenaValve Technology
    • 10.3.12. Leman Cardiovascular
    • 10.3.13. Micro Interventional Devices
    • 10.3.14. Neovasc
    • 10.3.15. On-X Life Technologies, Inc.
    • 10.3.16. Perouse Medical
    • 10.3.17. Sorin Group
    • 10.3.18. St. Jude Medical
    • 10.3.19. Symetis
    • 10.3.20. Transcatheter Technologies GmbH
    • 10.3.21. TTK Healthcare
    • 10.3.22. ValveXchange

11. Strategic Competitive Assessment

  • 11.1. Company Market Share
    • 11.1.1. Global Overview
    • 11.1.2. By Region
    • 11.1.3. By Country

12. Market Outlooks by Market Segment

  • 12.1. Market Segment Share
    • 12.1.1. Global
    • 12.1.2. By Region

13. Market Outlooks by Geography

  • 13.1. Global Overview
  • 13.2. US
  • 13.3. France
  • 13.4. Germany
  • 13.5. Italy
  • 13.6. Spain
  • 13.7. UK
  • 13.8. Japan
  • 13.9. China
  • 13.10. India
  • 13.11. Brazil

14. Appendix

  • 14.1. Bibliography
  • 14.2. Abbreviations
  • 14.3. Report Methodology
    • 14.3.1. Overview
    • 14.3.2. Coverage
    • 14.3.3. Secondary Research
  • 14.4. Forecasting Methodology
  • 14.5. Physicians and Specialists Included in This Study
  • 14.6. About the Authors
    • 14.6.1. Analysts
    • 14.6.2. Global Head of Healthcare
  • 14.7. About GlobalData
  • 14.8. Disclaimer

List of Tables

  • Table 1: Overview of Symptoms, Risk Factors, and Treatments
  • Table 2: Evolution of the Mechanical Heart Valve
  • Table 3: Evolution of the Tissue Heart Valve
  • Table 4: Comparison of Surgical and Transcatheter Procedures
  • Table 5: NYHA Functional Classification of Cardiac Disease Patients
  • Table 6: Drug Treatment Paradigm for Aortic Valve Disease
  • Table 7: Regulatory Differences Between the US and EU
  • Table 8: Medicare National Average of Inpatient Hospital Reimbursement for Valve Replacement, 2014-2015
  • Table 9: ICD-9 Coding Guide for Valvular Heart Disease, 2014
  • Table 10: Forecast Indirect National Costs For Aortic Valve Disease in the US ($bn), 2011-2020
  • Table 11: Forecast Indirect National Costs For Aortic Valve Disease in the EU ($bn), 2011-2020
  • Table 12: Minimum Arterial Diameter Required for TAVR Systems
  • Table 13: Global Projected Prevalence of Aortic Stenosis, 2013-2020
  • Table 14: Current Access Routes for Transcatheter Aortic Valve Replacement
  • Table 15: Mechanical Heart Valves, SWOT Analysis, 2014
  • Table 16: Marketed Mechanical Heart Valve Products, 2014
  • Table 17: Tissue Heart Valves, SWOT Analysis, 2014
  • Table 18: Marketed Tissue Heart Valve Products, 2014
  • Table 19: Transcatheter Heart Valves, SWOT Analysis, 2014
  • Table 20: Marketed Transcatheter Heart Valve Products, 2014
  • Table 21: Product Profile - Carbomedics Standard Aortic Mechanical Valve (Sorin Group)
  • Table 22: Carbomedics Standard Aortic Mechanical Valve, SWOT Analysis, 2014
  • Table 23: Product Profile - Open Pivot Mechanical Valve (Medtronic)
  • Table 24: Open Pivot Mechanical Valve, SWOT Analysis, 2014
  • Table 25: Product Profile - On-X Mechanical Heart Valve (On-X Life Technologies)
  • Table 26: On-X Mechanical Heart Valve, SWOT Analysis, 2014
  • Table 27: Product Profile - On-X Plus 1.5 Mechanical Heart Valve (On-X Life Technologies)
  • Table 28: On-X Plus 1.5 Mechanical Heart Valve, SWOT Analysis, 2014
  • Table 29: Product Profile - Regent Valve (St. Jude Medical)
  • Table 30: Regent Valve, SWOT Analysis, 2014
  • Table 31: Product Profile - Carpentier-Edwards Perimount Pericardial Valve (Edwards Lifesciences)
  • Table 32: Carpentier-Edwards Perimount Pericardial Valve, SWOT Analysis, 2014
  • Table 33: Product Profile - 3f Enable Sutureless Aortic Bioprosthesis (Medtronic)
  • Table 34: 3f Enable Sutureless Aortic Bioprosthesis, SWOT Analysis, 2014
  • Table 35: Product Profile - Hancock II (Medtronic)
  • Table 36: Medtronic Hancock II, SWOT Analysis, 2014
  • Table 37: Product Profile - Mitroflow Aortic Pericardial Heart Valve (Sorin Group)
  • Table 38: Sorin Group Mitroflow Aortic Pericardial Heart Valve, SWOT Analysis, 2014
  • Table 39: Product Profile - Trifecta Heart Valve (St. Jude Medical)
  • Table 40: St. Jude Medical Trifecta Heart Valve, SWOT Analysis, 2014
  • Table 41: Product Profile - Acurate TA/Acurate neo (Symetis)
  • Table 42: Acurate TA/Acurate neo, SWOT Analysis, 2014
  • Table 43: Product Profile - Lotus Valve System (Boston Scientific)
  • Table 44: Boston Scientific Lotus Valve System, SWOT Analysis, 2014
  • Table 45: Product Profile - Direct Flow Medical Transcatheter Valve (Direct Flow Medical)
  • Table 46: Direct Flow Medical Valve, SWOT Analysis, 2014
  • Table 47: Product Profile - Sapien XT Valve (Edwards Lifesciences)
  • Table 48: Sapien XT Valve, SWOT Analysis, 2014
  • Table 49: Product Profile - JenaValve (JenaValve Technology)
  • Table 50: JenaValve, SWOT Analysis, 2014
  • Table 51: Product Profile - CoreValve (Medtronic)
  • Table 52: CoreValve, SWOT Analysis, 2014
  • Table 53: Product Profile - CoreValve Evolut R (Medtronic)
  • Table 54: CoreValve Evolut R, SWOT Analysis, 2014
  • Table 55: Product Profile - Portico Valve (St. Jude Medical)
  • Table 56: Portico Valve, SWOT Analysis, 2014
  • Table 57: Product Profile - Inovare Valve (Braile Biomedica)
  • Table 58: Inovare Valve, SWOT Analysis, 2014
  • Table 59: Product Profile - Cytograft Tissue Valve (Cytograft Tissue Engineering)
  • Table 60: Cytograft Tissue Valve, SWOT Analysis, 2014
  • Table 61: Product Profile - Centera Valve (Edwards Lifesciences Corporation)
  • Table 62: Centera Valve, SWOT Analysis, 2014
  • Table 63: Product Profile - Colibri Heart Valve (Colibri Heart Valve)
  • Table 64: Colibri Heart Valve, SWOT Analysis, 2014
  • Table 65: Product Profile - Cormove (Perouse Medical)
  • Table 66: Cormove, SWOT Analysis, 2014
  • Table 67: Product Profile - Endovalve (Micro Interventional Devices)
  • Table 68: Endovalve, SWOT Analysis, 2014
  • Table 69: Product Profile - HLT Transcatheter Valve System (Heart Leaflet Technology)
  • Table 70: HLT Transcatheter Valve System, SWOT Analysis, 2014
  • Table 71: Product Profile - Kalangos Valve (Leman Cardiovascular)
  • Table 72: Kalangos Valve, SWOT Analysis, 2014
  • Table 73: Product Profile - Tiara Valve (Neovasc.)
  • Table 74: Tiara Valve, SWOT Analysis, 2014
  • Table 75: Product Profile - Trinity Valve (Transcatheter Technologies GmbH)
  • Table 76: Trinity VALVE, SWOT Analysis, 2014
  • Table 77: Product Profile - Vanguard Exchangeable Heart Valve System (ValveXchange)
  • Table 78: Vanguard Exchangeable Heart Valve System, SWOT Analysis, 2014
  • Table 79: AorTech International plc, Company Profile, 2014
  • Table 80: AorTech International, SWOT Analysis, 2014
  • Table 81: Boston Scientific Corporation, Company Profile, 2014
  • Table 82: Boston Scientific Corporation, SWOT Analysis, 2014
  • Table 83: Braile Biomedica, Company Profile, 2014
  • Table 84: Braile Biomedica, SWOT Analysis, 2014
  • Table 85: CardiAQ Valve Technologies, Company Profile, 2014
  • Table 86: CardiAQ Valve Technologies, SWOT Analysis, 2014
  • Table 87: Claret Medical, Inc., Company Profile, 2014
  • Table 88: Claret Medical, SWOT Analysis, 2014
  • Table 89: Colibri Heart Valve, LLC, Company Profile, 2014
  • Table 90: Colibri Heart Valve, SWOT Analysis, 2014
  • Table 91: Cytograft Tissue Engineering, Inc., Company Profile, 2014
  • Table 92: Cytograft Tissue Engineering, SWOT Analysis, 2014
  • Table 93: Direct Flow Medical, Inc., Company Profile, 2014
  • Table 94: Direct Flow Medical, SWOT Analysis, 2014
  • Table 95: Edwards Lifesciences Corporation, Company Profile, 2014
  • Table 96: Edwards Lifesciences, SWOT Analysis, 2014
  • Table 97: Heart Leaflet Technologies, Company Profile, 2014
  • Table 98: Heart Leaflet Technologies, SWOT Analysis, 2014
  • Table 99: JenaValve Technology, Company Profile, 2014
  • Table 100: JenaValve Technology, SWOT Analysis, 2014
  • Table 101: Leman Cardiovascular, Company Profile, 2014
  • Table 102: Leman Cardiovascular, SWOT Analysis, 2014
  • Table 103: Micro Interventional Devices, Inc., Company Profile, 2014
  • Table 104: Micro Interventional Devices, SWOT Analysis, 2014
  • Table 105: Neovasc, Inc., Company Profile, 2014
  • Table 106: Neovasc, SWOT Analysis, 2014
  • Table 107: On-X Life Technologies, Inc., Company Profile, 2014
  • Table 108: On-X Life Technologies, SWOT Analysis, 2014
  • Table 109: Perouse Medical, Company Profile, 2014
  • Table 110: Perouse Medical, SWOT Analysis, 2014
  • Table 111: Sorin Group, Company Profile, 2014
  • Table 112: Sorin Group, SWOT Analysis, 2014
  • Table 113: St. Jude Medical, Inc., Company Profile, 2014
  • Table 114: St. Jude Medical, Inc., SWOT Analysis, 2014
  • Table 115: Symetis, Company Profile, 2014
  • Table 116: Symetis, SWOT Analysis, 2014
  • Table 117: Transcatheter Technologies GmbH, Company Profile, 2014
  • Table 118: Transcatheter Technologies, SWOT Analysis, 2014
  • Table 119: TTK Healthcare, Company Profile, 2014
  • Table 120: TTK Healthcare, SWOT Analysis, 2014
  • Table 121: ValveXchange, Inc., Company Profile, 2014
  • Table 122: ValveXchange, SWOT Analysis, 2014
  • Table 123:Global Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 124:5EU Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 125:APAC Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 126:US Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 127:France Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 128:Germany Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 129:Italy Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 130:Spain Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 131:UK Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 132:Japan Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 133:China Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 134:India Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Table 135:Brazil Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020

List of Figures

  • Figure 1: Hierarchy of Valvular Heart Disease
  • Figure 2: Operative Risk for Severe, Symptomatic Aortic Valve Disease Patients, 2009
  • Figure 3: US Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 4: US Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 5: France Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 6: France Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 7: Germany Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 8: Germany Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 9: Italy Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 10: Italy Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 11: Spain Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 12: Spain Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 13: UK Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 14: UK Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 15: Japan Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 16: Japan Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 17: China Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 18: China Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 19: India Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 20: India Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 21: Brazil Procedure Volume Forecast by Market Segment, 2011-2020
  • Figure 22: Brazil Procedure Volume Comparison by Market Segment, 2013 & 2020
  • Figure 23: Global Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 24: EU Company Market Share for Prosthetic Heart Valves, 2012
  • Figure 25: APAC Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 26: US Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 27: France Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 28: Germany Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 29: Italy Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 30: Spain Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 31: UK Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 32: Japan Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 33: China Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 34: India Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 35: Brazil Company Market Shares for Prosthetic Heart Valves, 2012
  • Figure 36: Global Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011-2020
  • Figure 37: 5EU Market Value Forecast by Market Segment for Prosthetic Heart Valves, 2011-2020
  • Figure 38: APAC Market Value Forecast by Market Segment for Prosthetic Heart Valves, 2011-2020
  • Figure 39: Global Sales Volume for Prosthetic Heart Valves, Number of Units, 2011-2020
  • Figure 40: Global Market Value Forecast by Country, $m, 2011-2020
  • Figure 41: Global Market Share Comparison by Country, 2013 & 2020
  • Figure 42: US Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 43: US Market Value Comparison by Market Segment, 2013 & 2020
  • Figure 44: US Average Selling Price by Market Segment, 2011-2020
  • Figure 45: France Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 46: France Market Value Comparison by Market Segment, 2013 & 2020
  • Figure 47: France Average Selling Price by Market Segment, 2011-2020
  • Figure 48: Germany Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 49: Germany Market Value Comparison by Market Segment, 2013 & 2020
  • Figure 50: Germany Average Selling Price by Market Segment, 2011-2020
  • Figure 51: Italy Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 52: Italy Market Value Comparison by Market Segment, 2013 & 2020
  • Figure 53: Italy Average Selling Price by Market Segment, 2011-2020
  • Figure 54: Spain Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 55: Spain Market Value Comparison by Market Segment, 2013 & 2020
  • Figure 56: Spain Average Selling Price by Market Segment, 2011-2020
  • Figure 57: UK Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 58: UK Market Value Comparison By Market Segment, 2013 & 2020
  • Figure 59: UK Average Selling Price by Market Segment, 2011-2020
  • Figure 60: Japan Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 61: Japan Market Value Comparison by Market Segment, 2013 & 2020
  • Figure 62: Japan Average Selling Price by Market Segment, 2011-2020
  • Figure 63: China Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 64: China Market Value Comparison by Market Segment, 2013 & 2020
  • Figure 65: China Average Selling Price by Market Segment, 2011-2020
  • Figure 66: India Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 67: India Market Value Comparison by Market Segment, 2013 & 2020
  • Figure 68: India Average Selling Price by Market Segment, 2011-2020
  • Figure 69: Brazil Market Value Forecast by Market Segment, $m, 2011-2020
  • Figure 70: Brazil Market Value Comparison by Market Segment, 2013 & 2020
  • Figure 71: Brazil Average Selling Price by Market Segment, 2011-2020
Back to Top